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Abstract
Introduction: Increased activity of osteoclasts is responsible for bone loss and joint destruction in rheumatoid
arthritis. For osteoclast development and bone resorption activity, cytoskeletal organization must be properly
regulated. MicroRNAs (miRNAs) are endogenous small noncoding RNAs that suppress expression of their target
genes. This study was conducted to identify crucial miRNAs to control osteoclasts.
Methods: miRNA expression in the bone marrow-derived macrophages (BMM) with or without receptor activator
of nuclear factor B ligand (RANKL) stimulation was analyzed by miRNA array. To examine the role of specific
miRNAs in osteoclast formation, bone resorption activity and actin ring formation, the BMM were retrovirally
transduced with miRNA antagomirs. To confirm whether the suppressive effects on osteoclastogenesis by miR-31
inhibition were mediated by targeting RhoA, osteoclast formation was analyzed in the presence of the RhoA
inhibitor, exoenzyme C3.
Results: miR-31 was identified as one of the highly upregulated miRNAs during osteoclast development under
RANKL stimulation. Inhibition of miR-31 by specific antagomirs suppressed the RANKL-induced formation of
osteoclasts and bone resorption. Phalloidin staining of osteoclasts revealed that actin ring formation at the cell
periphery was severely impaired by miR-31 inhibition, and clusters of small ringed podosomes were observed
instead. In these osteoclasts, expression of RhoA, one of the miR-31 target genes, was upregulated by miR-31
inhibition in spite of the impaired osteoclastogenesis. Treatment with the RhoA inhibitor, exoenzyme C3, rescued
the osteoclastogenesis impaired by miR-31 inhibition.
Conclusions: miR-31 controls cytoskeleton organization in osteoclasts for optimal bone resorption activity by
regulating the expression of RhoA.
Introduction
Osteoclasts, the only cell type capable of resorbing
mineralized bone matrix, are derived from hematopoie-
tic precursor cells in the monocyte/macrophage lineage.
In collaboration with osteoblasts, osteoclasts play an
important role in physiologic bone remodeling to main-
tain adequate bone volume. In pathological conditions
such as osteoporosis and rheumatoid arthritis, increased
osteoclastic activity is responsible for bone loss or joint
destruction. Understanding the fine tuning of osteoclast
activity is important to explain their deregulated func-
tions in pathological conditions.
Cytoskeletal organization is dynamically regulated dur-
ing osteoclast maturation and bone resorption. Podosomes
are adhesion structures consisting of a column of actin
filaments surrounded by focal adhesion proteins. During
the maturation of osteoclasts, clusters of podosomes
assemble into podosome rings, and eventually into a podo-
some belt. On the mineralized matrix, a large and dense
actin ring called the sealing zone is formed. Osteoclasts
tightly attach to the bone matrix via the sealing zone to
dissolve the mineralized matrix [1]. These processes are
regulated by small GTPases, such as RhoA, Rac, CDC42,
RhoU and Arf6 [2]. However, how these pathways are
regulated during osteoclastogenesis and the bone resorp-
tion process is yet to be clarified.
The complex differentiation process of osteoclasts with
diverse functions has been explained by a number of
molecules and pathways including cytokines, transcription
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factors, adaptor proteins, kinases and phosphatases [3].
However, additional fine tuning may be required, since dif-
ferentiation of highly specialized cells is generally thought
to be strictly regulated with multiple checkpoints.
MicroRNAs (miRNAs) are noncoding small RNAs
about 22 nucleotides in length. By binding to their target
sites found mainly in 3’-untranslated regions of multiple
genes, miRNAs repress translation of target genes,
thereby suppressing the levels of expression. The biologi-
cal importance of miRNAs has been investigated in sev-
eral instances, revealing their involvement in fine tuning
of many biological processes such as cell proliferation,
differentiation and cell death in both physiological and
pathological conditions.
We and others have reported the importance of osteo-
clast miRNAs in vivo, and certain miRNAs have been
reported to be involved in osteoclast regulation [4-8].
Receptor activator of nuclear factor B ligand (RANKL)
induces expression of miR-21, and its silencing suppresses
osteoclastogenesis [6]. miR-155 deficiency suppressed
osteoclastogenesis and bone destruction in a murine
arthritis model [8]. miR-223 suppressed expression of
NFI-A, and inhibition of miR-223 impaired osteoclasto-
genesis [5]. However, the involvement of these miRNAs in
osteoclasts was examined based on previous reports about
their expression in other myeloid lineage cells such as
monocytes, macrophages and dendritic cells. Here we
directly investigated miRNA expression profiles of osteo-
clasts and identified miR-31 as a crucial miRNA to regu-
late cytoskeleton organization in these cells.
Materials and methods
Osteoclast formation
Bone marrow cells from 6-week-old to 10-week-old
DBA1J male mice were cultured in the presence of
20 ng/ml macrophage colony-stimulating factor
(M-CSF; R&D Systems, Minneapolis, MN, USA) for
2 days to induce bone marrow macrophages (BMMs).
BMMs were plated at 1.5 × 103 cells/cm2, and were
cultured in the presence of 20 ng/ml M-CSF and 5 to
50 ng/ml RANKL (R&D Systems) for 72 to 120 hours to
induce osteoclasts. Animal experiments were approved
by the animal welfare committee of Tokyo Medical and
Dental University.
miRNA array analysis
BMMs were cultured with 20 ng/ml M-CSF in the pre-
sence or absence of 50 ng/ml RANKL for 24 hours,
and were lysed for total RNA isolation. Cy3-labeled RNA
from control BMMs and Cy5-labeled RNA from RANKL-
treated BMMs were mixed and hybridized to the miRNA
array using the MiRVana™ MiRNA Bioarray system Ver.
2 (Ambion, Austin, TX, USA). Data were analyzed by
microarray data analysis tool software (Filgen, Nagoya,
Japan). The data have been deposited in the NCBI Gene
Expression Omnibus [GEO:GSE48629].
Reverse transcription and real-time quantitative PCR
For the real-time quantitative PCR analysis of miR-31,
Taq Man Gene Expression Assays (Applied Biosystems,
Foster City, CA, USA) were used. PCR was conducted
according to the manufacturer’s protocol. The expres-
sion levels of miR-31 were evaluated by calculating the
ratios against U6B expression levels.
Retroviral transduction
A miR-31-specific inhibitory oligonucleotide was cloned
into retroviral vector, pSilencer5.1-H1Retro (Ambion).
Sequences of the miR-31 inhibitory oligonucleotide were
as follows: sense, 5’-GATCCGAGCTATGCCAGCATCTT
GCCTTTTTTTGGAAA-3’; anti-sense, 5’-AGCTTTT
CCAAAAAAAGGCAAGATGCTGGCATAGCTCG-3’.
Bone marrow cells were cultured in the presence of
50 ng/ml M-CSF for 24 hours to induce BMMs. BMMs
were infected with miR-31 silencing (pSmiR31) or control
(pScontrol) virus for 6 hours, and cultured in the presence
of 6 μg/ml puromycin for 2 days. pMX-NFATc1 was pro-
vided by Dr Hiroshi Takayanagi (Tokyo University, Tokyo,
Japan) and has been described previously [9].
Pit formation assay
BMMs were cultured on Osteologic (BD Biosciences,
Bedford, MA, USA) in the presence of 20 ng/ml M-CSF
and 5 to 20 ng/ml RANKL for 6 days. Resorption lacu-
nae were visualized by dark-field light microscopy for
analysis with Image J software (NIH, Bethesda, MD,
USA).
Actin ring staining
After fixation, cells were incubated in 0.1% Triton X-100
in PBS for 5 minutes, and stained by Alexa Fluor 488
phalloidin (Molecular Probes, Eugene, OR, USA).
Western blot analysis
Total cell lysates were subjected to western blot analysis
with specific antibodies against RhoA (clone 67B7; Cell
Signaling, Danvers, MA, USA), c-Src (clone N-16; Santa
Cruz, Dallas, TX, USA), Pyk2 (clone H364; Cell Signal-
ing) and beta-actin (clone AC-15; Sigma Aldrich, St
Louis, MO, USA) together with peroxidase-conjugated
anti-rabbit or anti-mouse IgG as secondary antibodies.
RhoA activity assay
GTP-bound active RhoA was quantified using the G-LISA
RhoA activation assay biochem kit (Cytoskeleton, Denver,
CO, USA) according to the manufacturer’s protocol.
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Pharmacological RhoA inhibition
For the pharmacological RhoA inhibition, cell-permeable
exoenzyme C3 transferase (Cytoskeleton) was used.
After culturing BMMs in the presence of 20 ng/ml
M-CSF and 5 to 20 ng/ml RANKL for 24 hours, they
were further cultured in cell-permeable exoenzyme C3
containing medium for 48 hours. After tartrate-resistant
acid phosphatase (TRAP) staining, TRAP-positive multi-
nucleated cells were counted as osteoclasts.
Statistical evaluations
All of the numeral data in Results are presented as
mean ± standard deviation. Statistical analysis was per-
formed based on Student’s t test or Welch’s t test based
on the results of the F test.
Results
miR-31 is one of the highly upregulated miRNAs in
osteoclasts
To identify the miRNAs that are involved in osteoclasto-
genesis, we conducted a miRNA array and found 31
upregulated miRNAs and 11 downregulated miRNAs
(>1.5-fold) following RANKL stimulation (Figure 1A).
Of these miRNAs, we focused our analysis on one of
the highly upregulated miRNA, miR-31. In real-time
quantitative PCR analysis, expression of miR-31 in
BMM was low. However, RANKL treatment enhanced
miR-31 expression up to 18-fold (Figure 1B).
To examine whether the increased level of miR-31
during osteoclastogenesis is mediated by nuclear factor
of activated T-cells, cytoplasmic, calcineurin-dependent
1 (Nfatc1), a master transcription factor in osteoclasto-
genesis, Nfatc1 was retrovirally overexpressed in BMMs.
In real-time quantitative PCR analysis, overexpression of
Nfatc1 increased the level of Nfatc1 by about 20-fold,
compared with the empty vector control. However,
expression levels of miR-31 were not increased by the
overexpression of Nfatc1, indicating that the expression
of miR-31 is not regulated by Nfatc1 (Figure 1C).
Inhibition of miR-31 suppresses osteoclastogenesis and
bone resorption
To examine the role of miR-31 in osteoclastogenesis,
BMMs were treated with miR-31 antagomirs, which inhibit
binding of miR-31 to its target mRNAs. This antagomir
did not alter the expression levels of other miRNAs,
including miR-21, miR-155 and miR-223, which have been
reported to be involved in the regulation of osteoclast (see
Additional file 1). Under control conditions without the
antagomir treatment, ring-shaped TRAP-positive multinu-
cleated osteoclastic cells were observed after promotion of
osteoclast formation with RANKL for 72 hours. By
Figure 1 miR-31 is one of the highly upregulated microRNAs during osteoclastogenesis. (A) The profile of microRNA (miRNA) expression
levels was visualized by a scatter plot of signal intensities. Horizontal axis, cells treated with macrophage colony-stimulating factor (M-CSF) and
receptor activator of nuclear factor B ligand (RANKL) for 24 hours (BM-Oc); vertical axis, cells treated only with M-CSF (bone marrow
macrophage (BMM)). Dashed red lines indicate 1.5-fold upregulated or downregulated point, and miR-31 is indicated as a red dot. (B) Expression
of miR-31 during osteoclastogenesis was examined by real-time quantitative PCR at the indicated time points. Values were normalized against
U6B. RANKL treatment of BMMs (BM-Oc) enhanced the expression of miR-31. (C) Real-time quantitative PCR analysis of miR-31 after the
transduction with retroviruses encoding NFATc1 (pMX-NFATc1) or control viruses (pMX-control). Overexpression of NFATc1 did not increase the
level of miR-31. Nfatc1, nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1.
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contrast, when miR-31 was inhibited, the number of
TRAP-positive multinucleated cells was significantly
decreased, and ring-shaped mature osteoclastic cells were
rarely observed (Figure 2A). Osteoclasts generated under
miR-31 inhibition also resorbed a synthetic calcium phos-
phate matrix less efficiently than normal osteoclasts
(Figure 2B).
To examine whether decreased osteoclast formation via
miR-31 inhibition was caused by the impairment of the
fusion process, we cultured osteoclasts for 120 hours and
the number of TRAP-positive multinucleated cells was
evaluated. Following a period of these culture conditions,
the total number of TRAP-positive multinucleated cells
with miR-31 inhibition was equivalent to that of the con-
trol (Figure 2C). However, the number of ring-shaped
TRAP-positive multinucleated cells with miR-31 inhibition
was still less than the control (Figure 2C). These results
indicate that miR-31 does not affect the fusion process.
To study the pathways of miR-31 effects on osteoclasto-
genesis and bone resorption activities, real-time PCR was
conducted to analyze the expression of genes related to
osteoclast formation and maturation. Inhibition of miR-31
had no effect on Nfatc1, the master regulator of osteoclas-
togenesis, or on Trap or Cathepsin K (Figure 2D). These
results suggest that suppression of osteoclastogenesis and
bone resorption activity were attributable to inhibition at
the late stages of osteoclastogenesis.
Osteoclasts generated under miR-31 inhibition have
impaired actin ring formation
The sealing zone has to be formed for bone resorption by
osteoclasts. Since this formation is mediated by the organi-
zation of the actin cytoskeleton called the actin ring, we
examined actin ring formation in osteoclasts developed
under miR-31 inhibition. Without miR-31 inhibition, actin
fibers accumulated in the periphery of the osteoclast cyto-
plasm (Figure 2E, upper left panel). However, when miR-
31 was inhibited, peripheral actin rings were rarely formed
(Figure 2E, upper right panel). At high magnification, the
shape of the control-treated osteoclasts was round and the
edge of the cell was smooth, accompanying the accumula-
tion of actin fibers (Figure 2E, lower left panel). By contrast,
the shape of the miR-31-inhibited osteoclasts was not
round, but instead had an irregular edge. Instead of actin
rings in the periphery, ring-shaped small clusters of actin
were observed in the center of the cells (Figure 2E, lower
right panel). These results suggest that impaired osteoclast
formation and bone resorption resulting from miR-31 inhi-
bition are attributable to cytoskeleton disorganization.
Osteoclasts generated under miR-31 inhibition show
increased RhoA activity
We assumed that miR-31 should target the genes that
regulate cytoskeleton organization. Among them, we
focused on one of the GTPase, RhoA. RhoA has been
reported to be one of the targets of miR-31 in breast
cancer [10], and plays an important role as a molecular
switch in transducing extracellular signals to actin and
microtubule cytoskeleton [11]. In fact, osteoclasts with
miR-31 inhibition expressed increased levels of RhoA
protein (Figure 3A). GTP-bound active RhoA was also
increased by miR-31 inhibition, in spite of impaired
osteoclast formation (Figure 3B). In contrast, c-Src and
Pyk2 expression levels were not altered by miR-31 inhi-
bition (Figure 3C). These results argue that RhoA is a
target of miR-31 in osteoclasts.
Impaired osteoclastogenesis by miR-31 inhibition is
rescued by pharmacological RhoA inhibition
To determine whether the suppressive effect of miR-31
inhibition on osteoclasts could be mediated by increased
expression of RhoA, BMMs treated with the miR-31
antagomir were induced to osteoclasts in the presence of
the RhoA inhibitor, exoenzyme C3. A low concentration
of exoenzyme C3 rescued the decreased number of ring-
shaped TRAP-positive multinucleated cells caused by
miR-31 inhibition (Figure 3D, E). This result indicates
that impaired osteoclastogenesis caused by miR-31 inhi-
bition is due to excessive RhoA expression.
Discussion
In this study, we identified miR-31 as an important
miRNA in osteoclast regulation. Several miRNAs are
known to be involved in the regulation of osteoclasts
[5,6,8]. Unlike these other miRNAs, however, miR-31
has not been reported to have critical roles in other
hematopoietic myeloid lineage cells. Expression of miR-
31 was induced by RANKL, and it controlled osteoclas-
togenesis and bone resorption by regulating the cytoske-
leton organization.
Our results indicate that the main effect of miR-31
inhibition is to suppress the function of osteoclasts,
since bone resorption and actin ring formation were
severely suppressed by miR-31 inhibition in spite of the
normal expression of Nfatc1, Trap and Cathepsin K. In
addition, since osteoclast formation was also suppressed
by miR-31 inhibition, miR-31 might be involved in the
differentiation process as well, although the level was
moderate. We observed that miR-31 regulates cytoskele-
tal organization in osteoclasts. Cytoskeletal organization
is important in both osteoclast differentiation and the
resorption processes. Since expression level of miR-31
was increased during the osteoclast formation, miR-31
plays a role in the late phase of differentiation and the
resorption activity.
RhoA was identified as a miR-31 target gene in osteo-
clasts, where it regulates formation of actin stress fibers
and focal adhesions [12]. Inhibition of RhoA by exoenzyme
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C3 has been reported to inhibit both actin ring formation
and pit formation on dentine slices [13]. Furthermore,
transduction of active RhoA promoted actin ring formation
[14]. These results indicate that activation of RhoA is
essential for actin ring formation in osteoclasts. On the
other hand, inhibition of RhoA in the early stages of osteo-
clast differentiation increased the formation of actin ring-
positive mature osteoclasts [15]. Moreover, Pyk2-deficient
osteoclasts showed impaired sealing zone formation and
bone resorption via enhanced RhoA activity [16]. These
Figure 2 Osteoclasts generated under miR-31 inhibition show impaired osteoclastogenesis, bone resorption activities and actin ring
formation. (A) Tartrate-resistant acid phosphatase (TRAP) staining of osteoclasts after transduction with retroviruses encoding antagomirs of miR-31
(pSmiR31) or control viruses (pScontrol). Osteoclasts were developed in the presence of receptor activator of nuclear factor B ligand (RANKL) for
72 hours. Under conditions of miR-31 inhibition, although TRAP-positive multinucleated cells (MNCs) were formed, the frequency of ring-shaped
mature osteoclastic cells was decreased. The number of TRAP-positive MNCs was decreased by miR-31 inhibition (n = 5/group). (B) Pit formation assay.
Resorption lacunae were visualized in black by dark-field light microscopy. The resorbed area was decreased by miR-31 inhibition (n = 3/group).
(C) TRAP staining of osteoclasts that were developed in the presence of RANKL for 120 hours. The total number of TRAP-positive MNCs that were
generated under miR-31 inhibition was equivalent to that of control. The number of ring-shaped TRAP-positive MNCs that were generated under miR-
31 inhibition was less than that of control (n = 5/group). (D) Real-time PCR analysis of osteoclasts generated under miR-31 inhibition. Values were
normalized to glyceraldehyde 3-phosphate dehydrogenase expression. Expression levels of Nfatc1, Trap and Cathepsin K were not altered by miR-31
inhibitions (n = 3/group). (E) Actin-ring staining of osteoclasts. The number of actin ring-positive MNCs was decreased by miR-31 inhibition (upper
panels) (n = 3/group). Podosome organization at the cell periphery was observed in control osteoclasts (lower left panel), but not when miR-31 was
inhibited. Instead, small ring-shaped podosomes were observed (lower right panel). Green, Alexa 488 phalloidin; blue, 4’,6-diamidino-2-phenylindole.
**P < 0.01. Nfatc1, nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1.
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results demonstrated that excessive activity of RhoA also
suppresses osteoclastogenesis and sealing zone formation,
indicating that RhoA activity must be regulated tightly dur-
ing osteoclast formation and bone resorption.
During the process of osteoclastogenesis and bone
resorption, a regulator of RhoA expression must exist.
However, such RhoA regulatory systems in osteoclasts
had not yet been clarified. We observed that RhoA activ-
ities in osteoclasts were higher than in BMMs (data not
shown), and that expression of miR-31 was also increased
during osoteoclastogenesis. Therefore, we hypothesized
that miR-31 plays an important role in regulating the
expression of RhoA at an appropriate level to control
osteoclastogenesis and bone resorption.
The ability of exoenzyme C3 to rescue the impaired
osteoclastogenesis by miR-31 inhibition confirmed that
RhoA is a major target gene of miR-31 in osteoclasts.
However, its effect was partial, suggesting that miRNA
pleiotropically regulates the expression of multiple genes.
Other miR-31 target genes might also control osteoclast
development and function.
Our miRNA array analysis of osteoclasts revealed that
the miRNA expression profile was changed after stimu-
lation with RANKL. During osteoclastogenesis the gene
expression profile also changes, and this must be tightly
regulated. miRNA is one such regulatory system that we
have shown is involved in gene expression in osteoclasts.
Conclusions
miR-31 is one of the crucial molecules to finely control
the development and function of osteoclasts. Excessive
and insufficient activity of RhoA both suppressed osteo-
clastogenesis. Suppression by miR-31 should optimize
the expression of RhoA involved in cytoskeletal organi-
zation and following bone resorption.
Additional material
Additional file 1: Figure S1 showing real-time PCR analysis of
osteoclasts generated under miR-31 inhibition. Values were
normalized to U6B expression. Expression levels of miR-21, miR-155 and
miR-223 were not altered by miR-31 inhibitions (n = 3/group).
Figure 3 Impaired osteoclastogenesis by miR-31 inhibition is mediated by increased RhoA activity. (A) Western blot analysis of osteoclasts
after retroviral transduction of pSmiR31 or pScontrol. Expression of RhoA protein was increased in pSmiR31 transduced osteoclasts. (B) RhoA activity
was also increased by miR-31 inhibition. Values were normalized to RhoA activity of bone marrow macrophages (BMMs) (n = 3/group. **P < 0.01.
(C) Western blot analysis of osteoclasts. Expression of c-Src and Pyk2 protein were not altered in pSmiR31 transduced osteoclasts. (D), (E) Osteoclasts
were induced in the presence of the RhoA inhibitor; exoenzyme C3. A low concentration of exoenzyme C3 rescued the decreased number of ring-
shaped tartrate-resistant acid phosphatase (TRAP)-positive MNCs caused by miR-31 inhibition (n = 3/group). **P < 0.01. MNCs, multinucleated cells.
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